Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
39
ALXO Quote, Financials, Valuation and Earnings
Last price:
$1.31
Seasonality move
:
55.36%
Day range:
$1.27 - $1.37
52-week range:
$0.40 - $2.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.93x
P/B ratio:
1.61x
Volume:
74.6K
Avg. volume:
226.7K
1-year change:
-21.3%
Market cap:
$72.1M
Revenue:
--
EPS (TTM):
-$2.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALXO
ALX Oncology Holdings, Inc.
|
-- | -$0.26 | -- | -42.06% | $3.00 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $2.20 | 98.51% | -58.59% | $491.92 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
ERAS
Erasca, Inc.
|
-- | -$0.11 | -- | -4.86% | $5.13 |
|
IMRX
Immuneering Corp.
|
-- | -$0.35 | -- | -46.39% | $16.83 |
|
PRLD
Prelude Therapeutics, Inc.
|
-- | -$0.28 | 412.5% | -65.45% | $4.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALXO
ALX Oncology Holdings, Inc.
|
$1.33 | $3.00 | $72.1M | -- | $0.00 | 0% | 8.93x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$400.59 | $491.92 | $52.9B | 1,665.65x | $0.00 | 0% | 16.43x |
|
CVM
CEL-SCI Corp.
|
$4.71 | $42.50 | $14.3M | -- | $0.00 | 0% | -- |
|
ERAS
Erasca, Inc.
|
$3.48 | $5.13 | $987.3M | -- | $0.00 | 0% | -- |
|
IMRX
Immuneering Corp.
|
$6.73 | $16.83 | $434.6M | -- | $0.00 | 0% | 323.21x |
|
PRLD
Prelude Therapeutics, Inc.
|
$2.45 | $4.00 | $154M | -- | $0.00 | 0% | 16.52x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALXO
ALX Oncology Holdings, Inc.
|
25.84% | 3.782 | 15.92% | 2.19x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
ERAS
Erasca, Inc.
|
12.19% | 0.836 | 7.81% | 10.04x |
|
IMRX
Immuneering Corp.
|
1.69% | 6.410 | 0.88% | 23.84x |
|
PRLD
Prelude Therapeutics, Inc.
|
23.37% | -0.451 | 21.91% | 3.02x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALXO
ALX Oncology Holdings, Inc.
|
-$153K | -$22.5M | -101.77% | -120.56% | -- | -$17.1M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
ERAS
Erasca, Inc.
|
-$755K | -$32.5M | -28.42% | -32.03% | -- | -$21.7M |
|
IMRX
Immuneering Corp.
|
-$86.2K | -$15.4M | -74.71% | -78.54% | -- | -$12M |
|
PRLD
Prelude Therapeutics, Inc.
|
$6.1M | -$20.4M | -90.83% | -106.36% | -314.12% | -$19.1M |
ALX Oncology Holdings, Inc. vs. Competitors
-
Which has Higher Returns ALXO or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to ALX Oncology Holdings, Inc.'s net margin of 20.1%. ALX Oncology Holdings, Inc.'s return on equity of -120.56% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital ALXOALX Oncology Holdings, Inc.-- -$0.41 $60.4M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About ALXO or ALNY?
ALX Oncology Holdings, Inc. has a consensus price target of $3.00, signalling upside risk potential of 125.56%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 22.8%. Given that ALX Oncology Holdings, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe ALX Oncology Holdings, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALXOALX Oncology Holdings, Inc.3 1 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is ALXO or ALNY More Risky?
ALX Oncology Holdings, Inc. has a beta of 0.526, which suggesting that the stock is 47.364% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock ALXO or ALNY?
ALX Oncology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALX Oncology Holdings, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALXO or ALNY?
ALX Oncology Holdings, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. ALX Oncology Holdings, Inc.'s net income of -$22.1M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, ALX Oncology Holdings, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,665.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALX Oncology Holdings, Inc. is 8.93x versus 16.43x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALXOALX Oncology Holdings, Inc.8.93x -- -- -$22.1M ALNYAlnylam Pharmaceuticals, Inc.16.43x 1,665.65x $1.2B $251.1M
-
Which has Higher Returns ALXO or CVM?
CEL-SCI Corp. has a net margin of -- compared to ALX Oncology Holdings, Inc.'s net margin of --. ALX Oncology Holdings, Inc.'s return on equity of -120.56% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital ALXOALX Oncology Holdings, Inc.-- -$0.41 $60.4M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About ALXO or CVM?
ALX Oncology Holdings, Inc. has a consensus price target of $3.00, signalling upside risk potential of 125.56%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 802.34%. Given that CEL-SCI Corp. has higher upside potential than ALX Oncology Holdings, Inc., analysts believe CEL-SCI Corp. is more attractive than ALX Oncology Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALXOALX Oncology Holdings, Inc.3 1 0 CVMCEL-SCI Corp.1 0 0 -
Is ALXO or CVM More Risky?
ALX Oncology Holdings, Inc. has a beta of 0.526, which suggesting that the stock is 47.364% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock ALXO or CVM?
ALX Oncology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALX Oncology Holdings, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALXO or CVM?
ALX Oncology Holdings, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. ALX Oncology Holdings, Inc.'s net income of -$22.1M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, ALX Oncology Holdings, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALX Oncology Holdings, Inc. is 8.93x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALXOALX Oncology Holdings, Inc.8.93x -- -- -$22.1M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns ALXO or ERAS?
Erasca, Inc. has a net margin of -- compared to ALX Oncology Holdings, Inc.'s net margin of --. ALX Oncology Holdings, Inc.'s return on equity of -120.56% beat Erasca, Inc.'s return on equity of -32.03%.
Company Gross Margin Earnings Per Share Invested Capital ALXOALX Oncology Holdings, Inc.-- -$0.41 $60.4M ERASErasca, Inc.-- -$0.11 $396.2M -
What do Analysts Say About ALXO or ERAS?
ALX Oncology Holdings, Inc. has a consensus price target of $3.00, signalling upside risk potential of 125.56%. On the other hand Erasca, Inc. has an analysts' consensus of $5.13 which suggests that it could grow by 47.27%. Given that ALX Oncology Holdings, Inc. has higher upside potential than Erasca, Inc., analysts believe ALX Oncology Holdings, Inc. is more attractive than Erasca, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALXOALX Oncology Holdings, Inc.3 1 0 ERASErasca, Inc.6 1 0 -
Is ALXO or ERAS More Risky?
ALX Oncology Holdings, Inc. has a beta of 0.526, which suggesting that the stock is 47.364% less volatile than S&P 500. In comparison Erasca, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ALXO or ERAS?
ALX Oncology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Erasca, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALX Oncology Holdings, Inc. pays -- of its earnings as a dividend. Erasca, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALXO or ERAS?
ALX Oncology Holdings, Inc. quarterly revenues are --, which are smaller than Erasca, Inc. quarterly revenues of --. ALX Oncology Holdings, Inc.'s net income of -$22.1M is higher than Erasca, Inc.'s net income of -$30.6M. Notably, ALX Oncology Holdings, Inc.'s price-to-earnings ratio is -- while Erasca, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALX Oncology Holdings, Inc. is 8.93x versus -- for Erasca, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALXOALX Oncology Holdings, Inc.8.93x -- -- -$22.1M ERASErasca, Inc.-- -- -- -$30.6M
-
Which has Higher Returns ALXO or IMRX?
Immuneering Corp. has a net margin of -- compared to ALX Oncology Holdings, Inc.'s net margin of --. ALX Oncology Holdings, Inc.'s return on equity of -120.56% beat Immuneering Corp.'s return on equity of -78.54%.
Company Gross Margin Earnings Per Share Invested Capital ALXOALX Oncology Holdings, Inc.-- -$0.41 $60.4M IMRXImmuneering Corp.-- -$0.38 $231.9M -
What do Analysts Say About ALXO or IMRX?
ALX Oncology Holdings, Inc. has a consensus price target of $3.00, signalling upside risk potential of 125.56%. On the other hand Immuneering Corp. has an analysts' consensus of $16.83 which suggests that it could grow by 150.12%. Given that Immuneering Corp. has higher upside potential than ALX Oncology Holdings, Inc., analysts believe Immuneering Corp. is more attractive than ALX Oncology Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALXOALX Oncology Holdings, Inc.3 1 0 IMRXImmuneering Corp.4 0 0 -
Is ALXO or IMRX More Risky?
ALX Oncology Holdings, Inc. has a beta of 0.526, which suggesting that the stock is 47.364% less volatile than S&P 500. In comparison Immuneering Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ALXO or IMRX?
ALX Oncology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuneering Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALX Oncology Holdings, Inc. pays -- of its earnings as a dividend. Immuneering Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALXO or IMRX?
ALX Oncology Holdings, Inc. quarterly revenues are --, which are smaller than Immuneering Corp. quarterly revenues of --. ALX Oncology Holdings, Inc.'s net income of -$22.1M is lower than Immuneering Corp.'s net income of -$15M. Notably, ALX Oncology Holdings, Inc.'s price-to-earnings ratio is -- while Immuneering Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALX Oncology Holdings, Inc. is 8.93x versus 323.21x for Immuneering Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALXOALX Oncology Holdings, Inc.8.93x -- -- -$22.1M IMRXImmuneering Corp.323.21x -- -- -$15M
-
Which has Higher Returns ALXO or PRLD?
Prelude Therapeutics, Inc. has a net margin of -- compared to ALX Oncology Holdings, Inc.'s net margin of -303.46%. ALX Oncology Holdings, Inc.'s return on equity of -120.56% beat Prelude Therapeutics, Inc.'s return on equity of -106.36%.
Company Gross Margin Earnings Per Share Invested Capital ALXOALX Oncology Holdings, Inc.-- -$0.41 $60.4M PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M -
What do Analysts Say About ALXO or PRLD?
ALX Oncology Holdings, Inc. has a consensus price target of $3.00, signalling upside risk potential of 125.56%. On the other hand Prelude Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 63.27%. Given that ALX Oncology Holdings, Inc. has higher upside potential than Prelude Therapeutics, Inc., analysts believe ALX Oncology Holdings, Inc. is more attractive than Prelude Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALXOALX Oncology Holdings, Inc.3 1 0 PRLDPrelude Therapeutics, Inc.2 0 0 -
Is ALXO or PRLD More Risky?
ALX Oncology Holdings, Inc. has a beta of 0.526, which suggesting that the stock is 47.364% less volatile than S&P 500. In comparison Prelude Therapeutics, Inc. has a beta of 1.065, suggesting its more volatile than the S&P 500 by 6.517%.
-
Which is a Better Dividend Stock ALXO or PRLD?
ALX Oncology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prelude Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ALX Oncology Holdings, Inc. pays -- of its earnings as a dividend. Prelude Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALXO or PRLD?
ALX Oncology Holdings, Inc. quarterly revenues are --, which are smaller than Prelude Therapeutics, Inc. quarterly revenues of $6.5M. ALX Oncology Holdings, Inc.'s net income of -$22.1M is lower than Prelude Therapeutics, Inc.'s net income of -$19.7M. Notably, ALX Oncology Holdings, Inc.'s price-to-earnings ratio is -- while Prelude Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ALX Oncology Holdings, Inc. is 8.93x versus 16.52x for Prelude Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALXOALX Oncology Holdings, Inc.8.93x -- -- -$22.1M PRLDPrelude Therapeutics, Inc.16.52x -- $6.5M -$19.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
